Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LPO | P22079 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586280 | 0.85 | P2RX7 (0.74) | P2RX7 | |
| SCHEMBL3595866 | 0.84 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3581466 | 0.83 | P2RX7 (0.76) | P2RX7 | |
| SCHEMBL3595141 | 0.82 | P2RX7 (0.72) | P2RX7HTTLMNA | |
| SCHEMBL3591167 | 0.82 | P2RX7 (0.76) | P2RX7 | |
| SCHEMBL3588319 | 0.79 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3598129 | 0.78 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3600961 | 0.77 | P2RX7 (0.76) | P2RX7 | |
| SCHEMBL3593918 | 0.77 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL3579763 | 0.77 | P2RX7 (0.73) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885HTT 3489/4885SMN1; SMN2 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.